ED
EDTXF.US Spectral Med Inc
- Market cap
- USD 214M
- P/E
- -
- P/B
- 52.12x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EDTXF.US undervalued?
Graham numberThe Graham number of Spectral Med Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spectral Med Inc fundamental analysis
No fundamental analysis for Spectral Med Inc yet.
Spectral Med Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal …
Full company profileSpectral Med Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spectral Med Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.55M | 3.81M | 3.84M | 2.87M | 2.10M | 2.05M | 1.67M | 1.60M | 2.29M | 2.44M | 2.39M |
| Gross Profit | 2.84M | 3.33M | 3.47M | 2.22M | 1.47M | 1.22M | 983K | 662K | 1.02M | -5.15M | -2.19M |
| Operating Income | -10.2M | -3.94M | -1.60M | -4.71M | -9.09M | -8.60M | -9.44M | -15.3M | -12.0M | -11.7M | -9.86M |
| EBITDA | -9.23M | -3.17M | -1.89M | -4.55M | -8.76M | -6.38M | -7.70M | -14.0M | -12.0M | -11.4M | -4.18M |
| Net Income | -10.1M | -3.94M | -2.49M | -4.86M | -9.10M | -8.79M | -11.3M | -15.7M | -15.4M | -47.7M | 3.31M |
| EPS | -0.05 | -0.02 | -0.01 | -0.02 | -0.04 | -0.03 | -0.04 | -0.06 | -0.05 | -0.17 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 7.10M | 3.47M | 6.98M | 4.01M | 8.16M | 11.6M | 12.0M | 5.21M | 5.32M | 6.10M | 2.97M |
| Total Liabilities | 1.28M | 638K | 607K | 1.75M | 8.83M | 7.47M | 14.5M | 21.8M | 32.9M | 75.8M | 66.7M |
| Shareholders' Equity | 5.82M | 2.84M | 6.37M | 2.26M | -669K | 4.08M | -2.52M | -16.5M | -27.5M | -69.7M | -63.7M |
| Cash & Short-term Investments | 5.08M | 1.45M | 4.37M | 1.44M | 5.81M | 8.89M | 8.41M | 2.95M | 2.99M | 4.07M | 869K |
| Total Debt | 0.00 | 0.00 | 0.00 | 744K | 667K | 582K | 6.65M | 8.56M | 14.9M | 21.1M | 26.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.1M | -3.60M | -2.32M | -2.74M | -324K | -8.70M | -9.93M | -10.7M | -8.82M | -11.6M | -9.66M |
| Capital Expenditure | 122K | 135K | 47.0K | 161K | 315K | 483K | 33.0K | 185K | 27.0K | 195K | 0.00 |
| Free Cash Flow | -11.2M | -3.73M | -2.37M | -2.90M | -639K | -9.18M | -9.96M | -10.9M | -8.85M | -9.72M | -9.66M |
| Ratios | |||||||||||
| ROE | -174.3% | -138.9% | -39.1% | -215.0% | - | -215.2% | - | - | - | - | - |
| ROA | -142.9% | -113.4% | -35.7% | -121.3% | -111.5% | -76.0% | -93.8% | -300.6% | -289.5% | -781.8% | 111.6% |
| Net Profit Margin | -286.3% | -103.5% | -64.8% | -169.5% | -433.0% | -428.1% | -674.9% | -980.1% | -673.8% | -1,953.0% | 138.8% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.33x | - | 0.14x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spectral Med Inc dividends
Spectral Med Inc has not paid dividends in the last 9 fiscal years.
Who owns Spectral Med Inc
- Insiders 17.15%
- Institutions 12.35%
- Public & others 70.50%
- Shares outstanding 294M
- Free float 288M
Spectral Med Inc company profile
- Company name
- Spectral Med Inc
- Ticker
- EDTXF.US
- ISIN
- CA8475771033
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 135 The West Mall, Toronto, ON, Canada, M9C 1C2
- Phone
- 416-626-3233
- Website
- spectraldx.com
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Spectral Med Inc management
2- Mr. Christopher SetoCEO, Interim CFO & Director
- Prof. John A. Kellum M.D.Chief Medical Officer